What happened with NMAD today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Nomad Power Solutions, Inc. focuses its drug development on LB-100, an experimental drug intended to make other cancer treatments more effective by inhibiting an enzyme called PP2A. It is testing LB-100 in combination with other cancer therapies and aims to secure partnerships or licensing agreements with pharmaceutical companies that have major cancer programs. LB-100 is not approved for sale. Its colorectal-cancer study with atezolizumab at the Netherlands Cancer Institute is on hold while serious adverse events are investigated.
The company also owns a majority stake in Liora Technologies Europe Ltd., which is developing the LiGHT proton-therapy system. Liora plans to offer the system as an unlicensed prototype whose technology and engineering can be copied and licensed, rather than as equipment ready to treat patients. The prototype needs recommissioning; clinical use would require further work, funding and regulatory clearance.
Neither business currently generates revenue, and the company has no approved products. Investors supplying equity capital, rather than paying customers, fund operations. Continued development depends on access to more capital, while a future drug business depends on successful trials and regulatory approval.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Nomad's prospects hinge on LB-100 trial results and equity or licensing funding, while its unlicensed proton-therapy prototype faces established rivals such as IBA Worldwide.
Processa Pharmaceuticals, Inc. Common shares Nomad's need to prove it can improve existing cancer treatments: Processa aims to change how much active drug reaches cancer and healthy cells, while Nomad's LB-100 aims to boost drugs that damage cancer-cell DNA. Watch Processa's trial evidence on efficacy and tolerability—the same clinical hurdle matters as Nomad seeks partnerships or licensing agreements with pharmaceutical companies.
Processa Pharmaceuticals, Inc. earningsPCSA
Processa Pharmaceuticals’ report will show whether its cancer-drug trials are producing efficacy and tolerability evidence, the same clinical hurdles Nomad must clear to attract a partner for LB-100.
Read Processa’s efficacy evidence alongside tolerability: progress on both would show that a cancer-drug approach can clear clinical hurdles, giving context to Nomad’s effort to find a partner for LB-100; limited efficacy or tolerability problems would underscore the uncertainty of that route. Processa’s results cannot establish that LB-100 works or is safe, so Nomad’s own trials remain decisive.
